{"id":753813,"date":"2023-05-02T16:07:30","date_gmt":"2023-05-02T20:07:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/"},"modified":"2023-05-02T16:07:30","modified_gmt":"2023-05-02T20:07:30","slug":"acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/","title":{"rendered":"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023"},"content":{"rendered":"
\n

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc.<\/a> (NASDAQ: ABOS) (\u201cAcumen\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.<\/p>\n

To participate in the live conference call, please register using this\u202flink<\/a>. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.\u00a0<\/p>\n

The webcast audio will be available via this\u202flink<\/a>.\u00a0<\/p>\n

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company’s website at\u00a0www.acumenpharm.com<\/a>.<\/p>\n

\n About Acumen Pharmaceuticals, Inc.<\/strong>\n <\/p>\n

Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD). Acumen\u2019s scientific founders pioneered research on A\u03b2Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer\u2019s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble A\u03b2Os in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer\u2019s disease patients. For more information, visit\u00a0www.acumenpharm.com<\/a>.<\/p>\n

\n Investors: <\/strong>
\n
Alex Braun
abraun@acumenpharm.com<\/a><\/p>\n

\n Media:<\/strong>\u00a0
AcumenPR@westwicke.com<\/u><\/a>\u00a0<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (\u201cAcumen\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this\u202flink. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.\u00a0 The webcast audio will be available via this\u202flink.\u00a0 An … <\/p>\n

Continue reading “Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-753813","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAcumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (\u201cAcumen\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this\u202flink. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.\u00a0 The webcast audio will be available via this\u202flink.\u00a0 An … Continue reading "Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T20:07:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023\",\"datePublished\":\"2023-05-02T20:07:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/\"},\"wordCount\":273,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/\",\"name\":\"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI=\",\"datePublished\":\"2023-05-02T20:07:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/","og_locale":"en_US","og_type":"article","og_title":"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023 - Market Newsdesk","og_description":"CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (\u201cAcumen\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this\u202flink. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.\u00a0 The webcast audio will be available via this\u202flink.\u00a0 An … Continue reading \"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-02T20:07:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023","datePublished":"2023-05-02T20:07:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/"},"wordCount":273,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/","name":"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI=","datePublished":"2023-05-02T20:07:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDIyOSM1NTY5Nzc0IzIyMTA2ODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-9-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=753813"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753813\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=753813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=753813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=753813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}